oncgnostics GmbH
Germany
- Jena, Thüringen
- 11/09/2023
- Unknown
- Undisclosed Amount
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
- Industry Biotechnology Research
- Website https://www.oncgnostics.com/
- LinkedIn https://www.linkedin.com/company/oncgnostics/about/
Related People
Martina SchmitzFounder
Germany -
Jena, Thuringia
oncgnostics develops – based on proprietary epigenetic biomarkers - highly reliable molecular in vitro diagnostic (IVD) tests for screening, follow-up care and therapeutic decisions in cancer diagnostics.
First product is our CE IVD marked test "GynTect", a 2nd-line test for reliably detecting cervical cancer.
A short comic (german) explains what GynTect is doing.
On the Seedmatch-platform, there are a lot of insides on our company (german) and two nice videos about our company.
2016: https://www.seedmatch.de/startups/oncgnostics-2
2017: https://www.seedmatch.de/startups/oncgnostics
Forage | $40,000,000 | (Jun 5, 2026)
InCharge Energy | $46,000,000 | (Jun 5, 2026)
Oak Hill Bio | $32,500,000 | (Jun 5, 2026)
ZutaCore | $100,000,000 | (Jun 5, 2026)
Terra AI | $20,000,000 | (Jun 5, 2026)
Town | $55,000,000 | (Jun 5, 2026)
Lassie | $35,000,000 | (Jun 5, 2026)
OFFROAD | $7,000,000 | (Jun 5, 2026)
Shifters | $10,200,000 | (Jun 5, 2026)
Quobly | $133,545,475 | (Jun 5, 2026)
Scispot | $8,000,000 | (Jun 5, 2026)
Scotch | $20,000,000 | (Jun 5, 2026)